Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 82Carcinoma, Non-Small-Cell Lung 72Carcinoma, Renal Cell 42Neoplasm Metastasis 31Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Lung Neoplasms 25Colorectal Neoplasms 23Carcinoma, Hepatocellular 20Hodgkin Disease 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 14Carcinoma, Transitional Cell 13Head and Neck Neoplasms 12Urinary Bladder Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 11Multiple Myeloma 11Advanced Cancer 11Triple Negative Breast Neoplasms 10Lymphoma 10Glioblastoma 10Kidney Neoplasms 9Breast Neoplasms 9Recurrence 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Glioma 8Stomach Neoplasms 7Myelodysplastic Syndromes 7

Interventions

Sunitinib 3pembrolizumab 2pazopanib 2Axitinib 2aldesleukin 1Radiosurgery 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Ipilimumab 1Interleukin-2 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Clear-cell metastatic renal cell carcinoma × Nivolumab × Clear all
NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Bristol-Myers Squibb

Phase 1 Completed
194 enrolled 18 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡